+1-650-457-5617meetings@svicenter.com
+1-650-457-5617
meetings@svicenter.com

Visit BridgeBio

Developer of genetically targeted therapies intended to treat rare diseases

Select Meeting Details
BridgeBio

Extra services

We will confirm the details of your meeting after it is accepted by the host company

Developer of genetically targeted therapies intended to treat rare diseases. The company's approach is to combine traditional drug development with an unique corporate model, allowing rapid translation of early stage science into medicines that treat rare diseases at their source, enabling the patients with diseases across oncology, cardiology, dermatology, neurology and endocrinology to get advanced treatment.

Year Founded
2015
General Information
  • Website

    http://bridgebio.com

  • Business Status

    Generating Revenue

  • Ownership Status

    Privately Held (backing)

  • Financing Status

    Venture Capital-Backed

BridgeBio's Verticals
BridgeBio Primary Industry Sector / Group / Code
BridgeBio Status

The company raised $135 million of Series C venture funding in a deal led by Kohlberg Kravis Roberts and Viking Global Investors on April 10, 2018. American International Group, Aisling Capital, Perceptive Advisors, Cormorant Capital and Janus Capital Group also participated in the round. The new financing will be used to support BridgeBio Pharma's existing programs and establish novel efforts. The funding will also be used to establish up to another 10 of research-and-development subsidiaries.

BridgeBio Metrics
SimilarWeb Unique Visitors
Majestic Referring Domains
Headquarters
Get Directions
  • HQ Address Line 1
    421 Kipling Street
  • HQ City
    Palo Alto
  • HQ State/Province
    California
  • HQ Post Code
    94301
  • HQ Country
    United States
mood_bad
  • No comments yet.
    • chat
    Add a review

    Leave a Reply ·

    mood_bad
  • Feed is empty.

    • You May Also Be Interested In